The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $3.29

Today's change-0.27 -7.58%
Updated May 4 4:00 PM EDT. Delayed by at least 15 minutes.
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $3.29

Today's change-0.27 -7.58%
Updated May 4 4:00 PM EDT. Delayed by at least 15 minutes.

PDL BioPharma Inc crosses below 125-day moving average

PDL BioPharma Inc closed sharply lower Wednesday, dropping (U.S.)$0.27 or 7.58% to (U.S.)$3.29 and crossing below its 125-day moving average. Over the last five days, shares have lost 12.96% and are down 7.06% for the last year to date. This security has underperformed the S&P 500 by 46.93% during the last year.

Key company metrics

  • Open(U.S.) $3.51
  • Previous close(U.S.) $3.56
  • High(U.S.) $3.53
  • Low(U.S.) $3.22
  • Bid / Ask(U.S.) $3.42 / (U.S.) $3.91
  • YTD % change-7.06%
  • Volume3,201,210
  • Average volume (10-day)1,648,932
  • Average volume (1-month)1,645,628
  • Average volume (3-month)2,289,538
  • 52-week range(U.S.) $2.58 to (U.S.) $6.85
  • Beta0.71
  • Trailing P/E1.64×
  • P/E 1 year forward5.37×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.20
  • Dividend yield6.08%
  • Trailing EPS(U.S.) $2.01
Updated May 4 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.55%Sector:HealthcareIndustry:Biotechnology

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue178125138150
Total other revenue--------
Total revenue178125138150
Gross profit--------
Total cost of revenue--------
Total operating expense10878
Selling / general / administrative13878
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)-2000
Other operating expenses, total--------
Operating income168116131142
Interest income (expense), net non-operating-5-6-7-9
Gain (loss) on sale of assets--------
Other--------
Income before tax163110124134
Income after tax101697884
Income tax, total62414549
Net income101697884
Total adjustments to net income--------
Net income before extra. items101697884
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items101697884
Inc. avail. to common incl. extra. items101697884
Diluted net income101697885
Dilution adjustment------1
Diluted weighted average shares165164165170
Diluted EPS excluding extraordinary itemsvalue per share0.610.420.470.50
Dividends per sharevalue per share0.150.150.150.15
Diluted normalized EPSvalue per share0.600.420.470.50